Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response

BACKGROUND: In SELECT-COMPARE, a randomised double-blind study, upadacitinib 15 mg once daily was superior to placebo or adalimumab on background methotrexate (MTX) for treating rheumatoid arthritis signs and symptoms and inhibited radiographical progression versus placebo at 26 weeks. Here we repor...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleischmann, Roy M, Genovese, Mark C, Enejosa, Jeffrey V, Mysler, Eduardo, Bessette, Louis, Peterfy, Charles, Durez, Patrick, Ostor, Andrew, Li, Yihan, Song, In-Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6837258/
https://www.ncbi.nlm.nih.gov/pubmed/31362993
http://dx.doi.org/10.1136/annrheumdis-2019-215764

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6837258/
https://www.ncbi.nlm.nih.gov/pubmed/31362993
http://dx.doi.org/10.1136/annrheumdis-2019-215764

Ejemplares similares